Evidence map›Paper›PMID 36701154›Full record

ArticleJAMA network open2023

Development and Validation of Esophageal Squamous Cell Carcinoma Risk Prediction Models Based on an Endoscopic Screening Program.

Junming Han, Xiaolei Guo, Li Zhao, Huan Zhang, Siqi Ma, Yan Li, Deli Zhao, Jialin Wang, Fuzhong Xue

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Junming HanDepartment of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
Xiaolei GuoThe Department for Chronic and Noncommunicable Disease Control and Prevention, Shandong Center for Disease Control and Prevention and Academy of Preventive Medicine, Shandong University, Jinan, China.
Li ZhaoDepartment of Scientific Research and Teaching, Feicheng Hospital Affiliated to Shandong First Medical University, Feicheng, China.
Huan ZhangSchool of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Siqi MaSchool of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Yan LiCancer Prevention and Treatment Center, Feicheng People's Hospital, Feicheng, China.
Deli ZhaoCancer Prevention and Treatment Center, Feicheng People's Hospital, Feicheng, China.
Jialin WangSchool of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Fuzhong XueDepartment of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
Shandong First Medical University · CNShandong University · CNShandong Center for Disease Control and Prevention · CNShandong Tumor Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Assessment tools are lacking for screening of esophageal squamous cell cancer (ESCC) in China, especially for the follow-up stage. Risk prediction to optimize the screening procedure is urgently needed. Objective: To develop and validate ESCC prediction models for identifying people at high risk for follow-up decision-making. Design, Setting, and Participants: This open, prospective multicenter diagnostic study has been performed since September 1, 2006, in Shandong Province, China. This study used baseline and follow-up data until December 31, 2021. The data were analyzed between April 6 and May 31, 2022. Eligibility criteria consisted of rural residents aged 40 to 69 years who had no contraindications for endoscopy. Among 161 212 eligible participants, those diagnosed with cancer or who had cancer at baseline, did not complete the questionnaire, were younger than 40 years or older than 69 years, or were detected with severe dysplasia or worse lesions were eliminated from the analysis. Exposures: Risk factors obtained by questionnaire and endoscopy. Main Outcomes and Measures: Pathological diagnosis of ESCC and confirmation by cancer registry data. Results: In this diagnostic study of 104 129 participants (56.39% women; mean [SD] age, 54.31 [7.64] years), 59 481 (mean [SD] age, 53.83 [7.64] years; 58.55% women) formed the derivation set while 44 648 (mean [SD] age, 54.95 [7.60] years; 53.51% women) formed the validation set. A total of 252 new cases of ESCC were diagnosed during 424 903.50 person-years of follow-up in the derivation cohort and 61 new cases from 177 094.10 person-years follow-up in the validation cohort. Model A included the covariates age, sex, and number of lesions; model B included age, sex, smoking status, alcohol use status, body mass index, annual household income, history of gastrointestinal tract diseases, consumption of pickled food, number of lesions, distinct lesions, and mild or moderate dysplasia. The Harrell C statistic of model A was 0.80 (95% CI, 0.77-0.83) in the derivation set and 0.90 (95% CI, 0.87-0.93) in the validation set; the Harrell C statistic of model B was 0.83 (95% CI, 0.81-0.86) and 0.91 (95% CI, 0.88-0.95), respectively. The models also had good calibration performance and clinical usefulness. Conclusions and Relevance: The findings of this diagnostic study suggest that the models developed are suitable for selecting high-risk populations for follow-up decision-making and optimizing the cancer screening process.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaEndoscopy, GastrointestinalFemaleHumansMaleMiddle AgedProspective StudiesRisk Factors

Identifiers

PMID36701154
PMCPMC9880791
OpenAlexW4318070699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.